Cargando…

Assessment of the Anti-Thrombogenic Activity of Polyurethane Starch Composites

The increasing morbidity and mortality of patients due to post-surgery complications of coronary artery bypass grafts (CABPG) are related to blood–material interactions. Thus, the characterization of the thrombogenicity of the biomaterial for cardiovascular devices is of particular interest. This re...

Descripción completa

Detalles Bibliográficos
Autores principales: Cespedes, Jhoan F., Arévalo-Alquichire, Said, Diaz, Luis E., Valero, Manuel F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589968/
https://www.ncbi.nlm.nih.gov/pubmed/36278653
http://dx.doi.org/10.3390/jfb13040184
_version_ 1784814410883137536
author Cespedes, Jhoan F.
Arévalo-Alquichire, Said
Diaz, Luis E.
Valero, Manuel F.
author_facet Cespedes, Jhoan F.
Arévalo-Alquichire, Said
Diaz, Luis E.
Valero, Manuel F.
author_sort Cespedes, Jhoan F.
collection PubMed
description The increasing morbidity and mortality of patients due to post-surgery complications of coronary artery bypass grafts (CABPG) are related to blood–material interactions. Thus, the characterization of the thrombogenicity of the biomaterial for cardiovascular devices is of particular interest. This research evaluated the anti-thrombogenic activity of polyurethanes–starch composites. We previously synthesized polyurethane matrices that were obtained from polycaprolactone diol (PCL), polyethylene glycol (PEG), pentaerythritol (PE), and isophorone diisocyanate (IPDI). In addition, potato starch (AL-N) and zwitterionic starch (AL-Z) were added as fillers. The anti-thrombogenic property was characterized by the clot formation time, platelet adhesion, protein absorption, TAT complex levels, and hemolysis. Additionally, we evaluated the cell viability of the endothelial and smooth muscle cells. Statically significant differences among the polyurethane matrices (P1, P2, and P3) were found for protein absorption and the blood clotting time without fillers. The polyurethanes composites with AL-Z presented an improvement in the anti-thrombogenic property. On the other hand, the composites with AL-Z reduced the viability of the endothelial cells and did not significantly affect the AoSCM (except for P1, which increased). These results classify these biomaterials as inert; therefore, they can be used for cardiovascular applications.
format Online
Article
Text
id pubmed-9589968
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95899682022-10-25 Assessment of the Anti-Thrombogenic Activity of Polyurethane Starch Composites Cespedes, Jhoan F. Arévalo-Alquichire, Said Diaz, Luis E. Valero, Manuel F. J Funct Biomater Article The increasing morbidity and mortality of patients due to post-surgery complications of coronary artery bypass grafts (CABPG) are related to blood–material interactions. Thus, the characterization of the thrombogenicity of the biomaterial for cardiovascular devices is of particular interest. This research evaluated the anti-thrombogenic activity of polyurethanes–starch composites. We previously synthesized polyurethane matrices that were obtained from polycaprolactone diol (PCL), polyethylene glycol (PEG), pentaerythritol (PE), and isophorone diisocyanate (IPDI). In addition, potato starch (AL-N) and zwitterionic starch (AL-Z) were added as fillers. The anti-thrombogenic property was characterized by the clot formation time, platelet adhesion, protein absorption, TAT complex levels, and hemolysis. Additionally, we evaluated the cell viability of the endothelial and smooth muscle cells. Statically significant differences among the polyurethane matrices (P1, P2, and P3) were found for protein absorption and the blood clotting time without fillers. The polyurethanes composites with AL-Z presented an improvement in the anti-thrombogenic property. On the other hand, the composites with AL-Z reduced the viability of the endothelial cells and did not significantly affect the AoSCM (except for P1, which increased). These results classify these biomaterials as inert; therefore, they can be used for cardiovascular applications. MDPI 2022-10-12 /pmc/articles/PMC9589968/ /pubmed/36278653 http://dx.doi.org/10.3390/jfb13040184 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cespedes, Jhoan F.
Arévalo-Alquichire, Said
Diaz, Luis E.
Valero, Manuel F.
Assessment of the Anti-Thrombogenic Activity of Polyurethane Starch Composites
title Assessment of the Anti-Thrombogenic Activity of Polyurethane Starch Composites
title_full Assessment of the Anti-Thrombogenic Activity of Polyurethane Starch Composites
title_fullStr Assessment of the Anti-Thrombogenic Activity of Polyurethane Starch Composites
title_full_unstemmed Assessment of the Anti-Thrombogenic Activity of Polyurethane Starch Composites
title_short Assessment of the Anti-Thrombogenic Activity of Polyurethane Starch Composites
title_sort assessment of the anti-thrombogenic activity of polyurethane starch composites
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589968/
https://www.ncbi.nlm.nih.gov/pubmed/36278653
http://dx.doi.org/10.3390/jfb13040184
work_keys_str_mv AT cespedesjhoanf assessmentoftheantithrombogenicactivityofpolyurethanestarchcomposites
AT arevaloalquichiresaid assessmentoftheantithrombogenicactivityofpolyurethanestarchcomposites
AT diazluise assessmentoftheantithrombogenicactivityofpolyurethanestarchcomposites
AT valeromanuelf assessmentoftheantithrombogenicactivityofpolyurethanestarchcomposites